Prestige Consumer Healthcare Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
Prestige Consumer Healthcare Stock Forecast and Price Target
The average price target for Prestige Consumer Healthcare's stock lately set by several renowned analysts is $74.50, which would result in a potential upside of approximately 4.61% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $84.00 and a low estimate of $65.00. You may be interested in rivals even if you aren't interested in Prestige Consumer Healthcare stock.
4.61% Upside
Prestige Consumer Healthcare Fair Value Forecast for 2023 - 2025 - 2030
In the last five years, Prestige Consumer Healthcare has seen a decline in its Price, from $38.95 to $0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $60.54 – an increase of 100.00%. Over the next nine years, experts anticipate that Fair Value growth for Prestige Consumer Healthcare will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PG Stock Forecast | Procter & Gamble | Outperform |
12
|
$161.50 | Buy/Sell | $166.80 | 6.77% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.56 | Buy/Sell | $174.55 | 13.67% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$169.54 | Buy/Sell | $178.42 | 11.48% |
| ULVR Stock Forecast | Unilever PLC | Hold |
8
|
£38.61 | Buy/Sell | £50.61 | 28.62% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
88.85€ | Buy/Sell | 102.80€ | 22.68% |
Prestige Consumer Healthcare Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Prestige Consumer Healthcare has grown by 17.10%, going from $963.01M to $1.13B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $1.16B – an increase of 3.04%. Over the next six years, experts anticipate that Revenue growth for Prestige Consumer Healthcare will be 6.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDLZ Stock Forecast | Mondelez International | Buy |
15
|
$70.75 | Buy/Sell | $83.21 | 15.90% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.51 | Buy/Sell | £17.30 | 18.11% |
| MMM Stock Forecast | 3M | Hold |
10
|
$93.00 | Buy/Sell | $109.39 | 7.53% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF73.78 | Buy/Sell | CHF90.64 | 30.60% |
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
12
|
£42.50 | Buy/Sell | £66.68 | 35.29% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.35€ | Buy/Sell | 45.15€ | 17.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$106.71 | Buy/Sell | $96.90 | -0.95% |
| PHIA Stock Forecast | Koninklijke Philips N.V. | Hold |
18
|
19.60€ | Buy/Sell | 19.42€ | -0.51% |
| CLX Stock Forecast | Clorox Co-The | Hold |
16
|
$145.97 | Buy/Sell | $154.18 | 6.19% |
Prestige Consumer Healthcare EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Prestige Consumer Healthcare's EBITDA has grown, increasing from $329.35M to $380.43M – an increase of 15.51%. For next year, the 5 analysts predict EBITDA of $391.19M, which would mean an increase of 2.83%. Over the next seven years, the pros' prediction is EBITDAof $400.52M, which would mean a seven-year growth forecast of 5.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EBO Stock Forecast | EBOS Group | Hold |
18
|
$34.79 | Buy/Sell | $37.16 | 11.07% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.49 | Buy/Sell | $44.75 | 29.88% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.91 | Buy/Sell | $69.00 | 51.55% |
Prestige Consumer Healthcare EBIT Forecast for 2023 - 2025 - 2030
Prestige Consumer Healthcare's EBIT has increased by 15.79% In the last three years, going from $300.36M to $347.80M. In the next year, analysts expect EBIT to reach $361.84M – an increase of 4.04%. For the next eight years, the forecast is for EBIT to grow by 4.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EPC Stock Forecast | Edgewell Personal Care Co | Outperform |
14
|
$37.71 | Buy/Sell | $44.22 | 11.38% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.95 | Buy/Sell | $41.00 | 33.56% |
| TARO Stock Forecast | Taro Pharmaceutical Industries | Hold |
12
|
$42.23 | Buy/Sell | $43.00 | 1.82% |
Prestige Consumer Healthcare EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last five years, Prestige Consumer Healthcare has seen a decline in its EPS, from $2.96 to $0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $4.60 – an increase of 100.00%. Over the next nine years, experts anticipate that EPS growth for Prestige Consumer Healthcare will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$66.14 | Buy/Sell | $69.75 | 20.96% |
| SIG Stock Forecast | Sigma Healthcare | Hold |
12
|
$1.31 | Buy/Sell | $0.83 | -9.92% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$44.75 | Buy/Sell | $104.00 | 26.26% |
Site Navigation
.jpg)